Chromadex Corp (NASDAQ:CDXC) had its Buy rating reiterated by HC Wainwright with a $8.00 price target

ME Staff
-
0

Analyst Ratings For Chromadex Corp (NASDAQ:CDXC)

Today, HC Wainwright reiterated its Buy rating on Chromadex Corp (NASDAQ:CDXC) with a price target of $8.00.

There are 2 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.

The current consensus rating on Chromadex Corp (NASDAQ:CDXC) is Buy with a consensus target price of $7.50 per share, a potential 91.33% upside.

Some recent analyst ratings include

  • 9/10/2018-Chromadex Corp (NASDAQ:CDXC) had its Buy rating reiterated by HC Wainwright with a $8.00 price target
  • 9/25/2017-Chromadex Corp (NASDAQ:CDXC) has coverage initiated with a Buy ➝ Buy rating and $7.00 price target
  • 1/3/2017-Chromadex Corp (NASDAQ:CDXC) has coverage initiated with a Buy rating and $6.00 price target

Recent Insider Trading Activity For Chromadex Corp (NASDAQ:CDXC)
Chromadex Corp (NASDAQ:CDXC) has insider ownership of 10.26% and institutional ownership of 16.24%.

  • On 5/18/2018 Kevin M Farr, Insider, bought 5,000 with an average share price of $3.83 per share and the total transaction amounting to $19,150.00.
  • On 5/17/2018 Mark J Friedman, General Counsel, bought 3,000 with an average share price of $3.60 per share and the total transaction amounting to $10,800.00.
  • On 5/16/2018 Frank L Jaksch Jr, CEO, bought 9,800 with an average share price of $3.59 per share and the total transaction amounting to $35,182.00.
  • On 5/15/2018 Robert N Fried, COO, bought 10,000 with an average share price of $3.63 per share and the total transaction amounting to $36,300.00.
  • On 3/29/2018 Frank L Jaksch Jr, CEO, sold 474 with an average share price of $4.60 per share and the total transaction amounting to $2,180.40.
  • On 3/27/2018 Frank L Jaksch Jr, CEO, sold 24,578 with an average share price of $4.60 per share and the total transaction amounting to $113,058.80.
  • On 1/11/2018 Frank L Jaksch Jr, CEO, sold 28,379 with an average share price of $6.52 per share and the total transaction amounting to $185,031.08.

About Chromadex Corp (NASDAQ:CDXC)
ChromaDex Corporation operates as a nutraceutical company. The company offers research and quality control products and services to dietary supplements, food, beverages, cosmetic, and pharmaceutical industries; Nicotinamide riboside (NIAGEN), a novel form of vitamin B3 for enhancing nicotinamide adenine dinucleotide(NAD) level used for healthy aging; Pterostilbene (pTeroPure), a polyphenol and antioxidant used in health related fields; and Immulina, a spirulina extract and compound, which is used for improving human immune function, as well as developing Pterostilbene and caffeine co-crystal ingredients, and anthocyanins ingredients. It also provides reference standards, materials, and kits to conduct quality control of raw materials and consumer products; and fine chemicals and phytochemicals for research and new product development applications. In addition, the company offers a range of consulting services, including regulatory support, product development, risk management, and litigation support. Further, it assists customers in creating processes for manufacturing natural products using green chemistry, as well as developing phytochemical libraries. The company markets and sells its products directly in the United States and Canada; and through international distributors. ChromaDex Corporation is based in Irvine, California.

Recent Trading Activity for Chromadex Corp (NASDAQ:CDXC)
Shares of Chromadex Corp closed the previous trading session at 3.92 −0.39 9.05% with 495200 shares trading hands.